News
Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1
SAN DIEGO, CA / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its...
Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 productSAN DIEGO, CA / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch...
Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations-CEO to discuss...
Registration Is Now Open For Tribe Public’s Webinar Event “Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity” Featuring Modular Medical CEO On Wednesday, September 11, 2024
Meet with Modular Medical CEO, Jeb BesserThere are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.Obesity is linked to...
Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
SAN DIEGO, CA / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay...
Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / September 4,...
Registration is Now Open for Tribe Public’s Webinar Event “Diabetes Care Innovator Modular Medical Takes Next Steps” Featuring Modular Medical CEO on Friday, August 9, 2024
The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032Discover how Modular Medical is accelerating the development of...
Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize
SAN DIEGO, CA / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology,...
Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD)...
Modular Medical Announces Addition to the Russell Microcap® Index
SAN DIEGO, CA / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is...